NO931151D0 - Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer - Google Patents

Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer

Info

Publication number
NO931151D0
NO931151D0 NO931151A NO931151A NO931151D0 NO 931151 D0 NO931151 D0 NO 931151D0 NO 931151 A NO931151 A NO 931151A NO 931151 A NO931151 A NO 931151A NO 931151 D0 NO931151 D0 NO 931151D0
Authority
NO
Norway
Prior art keywords
nitrogen containing
procedure
preparation
containing heterocyclic
heterocyclic compounds
Prior art date
Application number
NO931151A
Other languages
English (en)
Norwegian (no)
Other versions
NO931151L (no
Inventor
Manoj C Desai
Harry R Howard
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO931151L publication Critical patent/NO931151L/no
Publication of NO931151D0 publication Critical patent/NO931151D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Eye Examination Apparatus (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Electroluminescent Light Sources (AREA)
NO931151A 1990-09-28 1993-03-26 Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer NO931151D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59042390A 1990-09-28 1990-09-28
PCT/US1991/005776 WO1992006079A1 (en) 1990-09-28 1991-08-20 Fused ring analogs of nitrogen containing nonaromatic heterocycles

Publications (2)

Publication Number Publication Date
NO931151L NO931151L (no) 1993-03-26
NO931151D0 true NO931151D0 (no) 1993-03-26

Family

ID=24362216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931151A NO931151D0 (no) 1990-09-28 1993-03-26 Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer

Country Status (22)

Country Link
EP (1) EP0550635B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0772175B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1060285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE121389T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU651145B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9106905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2089736A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ387492A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69109125T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0550635T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2071334T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI931370A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT68667A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE66042B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL99525A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9101274A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO931151D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT99064A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW199144B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1992006079A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU159291A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA917744B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
PL170516B1 (en) * 1991-06-20 1996-12-31 Pfizer Method of obtaining novel derivatives of fluoroalkoxy benzylaminic compounds of piperidine
TW202432B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-06-21 1993-03-21 Pfizer
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
FI942187A0 (fi) * 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
JPH07506379A (ja) * 1992-08-04 1995-07-13 ファイザー・インコーポレーテッド 物質ｐ受容体アンタゴニストとしての３−ベンジルアミノ−２−フェニル−ピペリジン
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
AU4224993A (en) * 1992-08-19 1994-03-15 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6144098A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
JP2000510870A (ja) * 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Ｎｐｙ５受容体アンタゴニストとしてのアミド類
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
DE60038185T2 (de) 1999-11-03 2009-02-19 Amr Technology, Inc. Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CZ20023213A3 (cs) * 2000-04-10 2003-12-17 Pfizer Products Inc. Benzoamidové piperidinové sloučeniny a příbuzné sloučeniny
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
NZ523456A (en) 2000-07-11 2004-11-26 Albany Molecular Res Inc Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
WO2002030888A2 (en) * 2000-10-10 2002-04-18 Calyx Therapeutics, Inc. Tricyclic compounds and uses thereof
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0617867D0 (en) * 2006-09-11 2006-10-18 Glaxo Group Ltd Chemical compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
GB0716573D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Chemical compounds
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
GB0804326D0 (en) * 2008-03-07 2008-04-16 Glaxo Group Ltd Novel compounds
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
BR112015006990A2 (pt) 2012-09-28 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de pelo menos um composto
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104610146A (zh) * 2015-01-23 2015-05-13 常州大学 一种3-氮杂二环[5,1,0]-7-醛及合成方法
CN105330588B (zh) * 2015-10-16 2017-09-26 辽宁中医药大学 马齿苋中生物碱Oleracone及其提取分离方法
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MX2021001486A (es) 2018-08-07 2021-07-15 Merck Sharp & Dohme Llc Inhibidores prmt5.
CN113121427B (zh) * 2021-03-19 2022-04-01 广东工业大学 一种喹啉类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452026A (en) * 1966-03-15 1969-06-24 Bristol Myers Co Substituted 1,2,3,4-tetrahydroquinolines
FR1555552A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1967-07-05 1969-01-31
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists

Also Published As

Publication number Publication date
WO1992006079A1 (en) 1992-04-16
FI931370L (fi) 1993-03-26
TW199144B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-02-01
CA2089736A1 (en) 1992-03-29
DE69109125T2 (de) 1995-09-28
YU159291A (sh) 1994-01-20
ATE121389T1 (de) 1995-05-15
DE69109125D1 (de) 1995-05-24
AU8746391A (en) 1992-04-28
FI931370A0 (fi) 1993-03-26
AU651145B2 (en) 1994-07-14
CN1060285A (zh) 1992-04-15
EP0550635A1 (en) 1993-07-14
JPH06501267A (ja) 1994-02-10
ES2071334T3 (es) 1995-06-16
HU9300898D0 (en) 1993-06-28
ZA917744B (en) 1993-03-29
JPH0772175B2 (ja) 1995-08-02
IE913396A1 (en) 1992-04-08
NO931151L (no) 1993-03-26
HUT68667A (en) 1995-07-28
FI931370A7 (fi) 1993-03-26
IE66042B1 (en) 1995-12-13
EP0550635B1 (en) 1995-04-19
BR9106905A (pt) 1993-08-17
CZ387492A3 (en) 1994-02-16
PT99064A (pt) 1992-08-31
MX9101274A (es) 1992-05-04
DK0550635T3 (da) 1995-09-04
IL99525A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
NO931151D0 (no) Fremgangsmaate for fremstilling av nitrogenholdige heterocykliske forbindelser med kondenserte ringer
GR3026231T3 (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
CA2118704A1 (en) Fused Tricyclic Nitrogen Containing Heterocycles as Substance P Receptor Antagonists
BR1100086A (pt) Derivados de fluoralcóxibenzilamino de heterocìclos contendo nitrogênio
EA200100970A1 (ru) Аминопроизводные как ингибиторы протеазы
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
PT92494A (pt) Processo para a preparacao de novos derivados do indol
RU94019331A (ru) Конденсированные трициклические азотсодержащие гетероциклы, фармацевтическая композиция, способ лечения
SE8802162D0 (sv) Nya aminoacylater av glycerolacetal